| Type | Title | Date Released | |
|---|---|---|---|
6-K | Chemomab Therapeutics Incorporates Registration Statement Information Regarding Proposed Merger with Scipher Medicine | ||
EFFECT | Form EFFECT | ||
DEFM14A | Form DEFM14A | ||
S-4/A | Form S-4/A | ||
6-K | Chemomab Therapeutics Amends Merger Agreement and CVR Terms for U.S. Redomiciliation with Scipher Medicine | ||
S-4/A | Form S-4/A | ||
6-K | Chemomab Therapeutics Enters into Amendment No. 1 to Merger Agreement for U.S. Redomiciliation and Combination with Scipher Medicine | ||
S-4 | Form S-4 | ||
SCHEDULE 13D/A | HBM Healthcare Investments (Cayman) Ltd. (Filed by) | ||
4 | Cohen Neil Harris (Reporting) | ||
6-K | Chemomab Therapeutics Ltd. Interim Financial Results for the Period Ended June 30, 2026 | ||
SCHEDULE 13G | Touchstone Global Investments Pty Ltd (Filed by) |
